Results 21 to 30 of about 26,340 (266)

Influence of Sacubitril/Valsartan (LCZ696) on 30-day readmission after heart failure hospitalization [PDF]

, 2016
Background: Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization. Objectives: This study sought to determine if treatment with sacubitril/valsartan (LCZ696) reduces rates ...
Claggett, Brian L., Desai, Akshay S., Lefkowitz, Martin, McMurray, John J.V., Packer, Milton, Rouleau, Jean L., Shi, Victor, Solomon, Scott D., Starling, Randall, Swedberg, Karl, Teerlink, John, Zile, Michael R.   +11 more
core   +2 more sources

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm [PDF]

, 2016
Many conditions culminate in heart failure (HF), a multi-organ systemic syndrome with an intrinsically poor prognosis. Pharmacotherapeutic agents that correct neurohormonal dysregulation and haemodynamic instability have occupied the forefront of ...
Abozguia, AIRE Study Group, Alexander, Alexander, Alexander, Alexander, Ashrafian, Bailey, Bailey, Basu, Beadle, Braunwald, Brown, Burgoyne, Chaitman, Chatterjee, Chung, CIBIS-II Study Group, Cleland, Clerc, Cohn, Cohn, Cohn, CONSENSUS Trial Study Group, Conway, Cook, Dai, Digitalis Investigation Group, Doenst, Dzau, Dzau, Faris, Flather, Follath, Foster, Fox, Fox, Fragasso, Furberg, Gheorghiade, Gladwin, Goffart, Granger, Greenberg, Guazzi, Guazzi, Heymans, Hobbs, Holubarsch, Horowitz, Horowitz, Kantor, Kapil, Kato, Kennedy, Kennedy, Kostis, Larsen, Lee, Lopaschuk, Luiken, Lundberg, Maher, Maier, Mancini, Mann, Mann, Massie, Mccormack, Mcdowell, Mcmurray, Mcmurray, Merit-Hf Study Group, Munzel, Munzel, Neglia, Neubauer, Ormerod, Packer, Packer, Paul, Pawson, Pfeffer, Pfeffer, Pitt, Pitt, Rathore, Rauchhaus, Redfield, Rona, Sack, Sarraf, Schmidt-Schweda, Schrauwen, Schwarz, Shah, Shah, Siddiqi, Singh, SOLVD Investigators, Stanley, Swedberg, Szwed, Taylor, Teerlink, Tilemann, Torre-Amione, Totzeck, Turcani, Unger, Van Der Vusse, Van Faassen, Vardeny, Webb, Yin, Yusuf, Zamani, Zannad, Zannad, Zhang   +119 more
core   +1 more source

Combined drug sacubitril/valsartan -a new era of treatment of chronic heart failure

Медицинский совет, 2020
The article describes the possibility of using a new class of angiotensin II/neprilysin receptor inhibitor - sacubitrile/valsartan for the treatment of chronic heart failure (CHF). The role of the natriuretic peptide system in the pathogenesis of CHF and
V. S. Nikiforov
doaj   +1 more source

Association between soluble neprilysin and diabetes: Findings from a prospective longitudinal study

Frontiers in Endocrinology, 2023
BackgroundThe potential role of neprilysin (NEP) in glucose metabolism has been found by basic studies but lacks population evidence. The objective of this study was to examine the association between serum NEP and diabetes in Chinese adults.MethodsIn a ...
Junting Hu, Hanyun Zhu, Yunlang Dai, Yang Liu, Ying Lu, Shasha Zhu, Linan Chen, Mingzhi Zhang, Tingbo Jiang, Hao Peng, Hao Peng   +10 more
doaj   +1 more source

Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2018
Aims: Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but conventional analyses consider only the first event. We compared the effect of sacubitril/valsartan vs.
Abraham, Andersen, Anker, Anker, Borer, Ghosh, Greenberg, Lin, McMurray, McMurray, Metcalfe, Neaton, Packer, Rogers, Rogers, Rogers, Rogers, Solomon, Wei   +18 more
core   +3 more sources

Angiotensin receptor blocker neprilysin inhibitors

World Journal of Cardiology, 2021
Heart failure (HF) is a clinical syndrome that results from a structural or functional cardiac disorder that reduces the ability of the ventricle of the heart to fill with, or eject, blood. It is a multifaceted clinical condition that affects up to 2% of the population in the developed world, and is linked to significant morbidity and mortality; it is ...
Usuda, Daisuke, Higashikawa, Toshihiro, Hotchi, Yuta, Usami, Kenki, Shimozawa, Shintaro, Tokunaga, Shungo, Osugi, Ippei, Katou, Risa, Ito, Sakurako, Yoshizawa, Toshihiko, Asako, Suguru, Mishima, Kentaro, Kondo, Akihiko, Mizuno, Keiko, Takami, Hiroki, Komatsu, Takayuki, Oba, Jiro, Nomura, Tomohisa, Sugita, Manabu   +18 more
openaire   +2 more sources

Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy [PDF]

, 2016
Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the ...
Gong, Jianjian, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Okumura, Naoki, Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +2 more sources

Neprilysin Deficiency Protects Against Fat-Induced Insulin Secretory Dysfunction by Maintaining Calcium Influx [PDF]

, 2014
Neprilysin contributes to free fatty acid (FFA)-induced cellular dysfunction in nonislet tissues in type 2 diabetes. Here, we show for the first time that with prolonged FFA exposure, islet neprilysin is upregulated and this is associated with reduced ...
Andrikopoulos, Sofianos, Barrow, Breanne M., Kahn, Steven E., Koh, Duk-Su, Lu, Bao, Zraika, Sakeneh   +5 more
core   +1 more source

Autocrine regulation of human sperm motility by tachykinins

Reproductive Biology and Endocrinology, 2010
Background We examined the presence and function of tachykinins and the tachykinin-degrading enzymes neprilysin (NEP) and neprilysin-2 (NEP2) in human spermatozoa.
Pinto Francisco M, Ravina Cristina G, Subiran Nerea, Cejudo-Román Antonio, Fernández-Sánchez Manuel, Irazusta Jon, Garrido Nicolas, Candenas Luz   +7 more
doaj   +1 more source

Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF [PDF]

, 2017
Background: Compared to heart failure patients with higher systolic blood pressure (SBP), those with lower SBP have a worse prognosis. To make matters worse, the latter patients often do not receive treatment with life-saving therapies that might ...
Böhm, Michael, Gong, Jianjian, Jhund, Pardeep, Lefkowitz, Martin P., McMurray, John J.V., Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Young, Robin, Zile, Michael R.   +12 more
core   +1 more source